Abdominal metastases from colorectal cancer: intraperitoneal therapy
- PMID: 26697203
- PMCID: PMC4671857
- DOI: 10.3978/j.issn.2078-6891.2015.078
Abdominal metastases from colorectal cancer: intraperitoneal therapy
Abstract
Patients with peritoneal metastasis from colorectal cancer represent a distinct subset with regional disease rather than systemic disease. They often have poorer survival outcomes with systemic chemotherapy. Optimal cytoreductive surgery and intraperitoneal chemotherapy (IPC) offers such patients a more directed therapy with improved survival. In this review, we discuss the diagnosis, evaluation and classification, as well as rational for treatment of peritoneal carcinomatosis (PC) secondary to colorectal cancer.
Keywords: Colorectal peritoneal carcinomatosis (PC); cytoreductive surgery; intraperitoneal chemotherapy (IPC).
Conflict of interest statement
References
-
- van Gestel YR, de Hingh IH, van Herk-Sukel MP, et al. Patterns of metachronous metastases after curative treatment of colorectal cancer. Cancer Epidemiol 2014;38:448-54. - PubMed
-
- Segelman J, Granath F, Holm T, et al. Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancer. Br J Surg 2012;99:699-705. - PubMed
-
- Chua TC, Liauw W, Chu F, et al. Viewing metastatic colorectal cancer as a curable chronic disease. Am J Clin Oncol 2012;35:77-80. - PubMed
-
- Klaver YL, Simkens LH, Lemmens VE, et al. Outcomes of colorectal cancer patients with peritoneal carcinomatosis treated with chemotherapy with and without targeted therapy. Eur J Surg Oncol 2012;38:617-23. - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources